Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
In patients with unresectable/advanced Hepatocellular Carcinoma receiving Capecitabin, we
anticipate that the proposed chemotherapy will have a delay in progression of the disease .
It is also expected that proposed chemotherapy will have acceptable toxicity and Quality of
life.